XOMA 129 is a highly potent fragment of a monoclonal antibody (“Fab”) with negative allosteric modulation activity against the insulin receptor that was derived from the XMetD program. In animal model testing, it appears to have a fast-onset of action and short half-life.
Hypoglycemia is a serious medical condition in patients with Type 2 diabetes and Type 1 diabetes and can occur as a result of insulin therapy, accidental insulin overdose or treatment with sulfonylureas. Recurrent hypoglycemia leads to diminished recognition of the symptoms, which include palpitations, tremors, anxiety, sweating, and hunger. This reduced sensitivity to hypoglycemic symptoms can lead to more prolonged episodes and the advancement into acute severe hypoglycemia, which can result in confusion, loss of consciousness, and seizure.
Acute severe hypoglycemia often presents during the nocturnal hours in patients who are treated aggressively for their Type 1 diabetes, which puts them at elevated risk for loss of consciousness and seizure. The medical community has long been challenged with how to prevent patients from experiencing nocturnal acute severe hypoglycemia, yet there have not been any significant breakthroughs in pharmaceutical development efforts or experiments in dietary practices.
We presented the first preclinical data of XOMA 129 at the Endocrine Society's Annual Meeting in April (ENDO 2016.) We are conducting additional preclinical tests and intend to advance it into Phase 1 testing as soon as practicable. We believe XOMA 129 could potentially offer clinicians a therapy that has rapid onset, improved efficacy and optimal duration of therapy to treat patients with acute severe hypoglycemia wherein currently available therapies are inadequate.